Physician profile
Anza B Memon
NPI 1497060818
$8,409.54
in general payments reported to CMS, 2019-2025
10 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.00 · 2022: $314 · 2023: $7,549 · 2024: $133 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,050 · Travel and Lodging: $974 · Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,050.00 |
| Travel and Lodging | $974.00 |
| Food and Beverage | $972.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $7,549.27 | 2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $282.23 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $169.02 | 2022 | |
| Genentech USA, INC. | $145.38 | 2022 | |
| Tg Therapeutics, INC. | $113.58 | 2025 | |
| Janssen Pharmaceuticals, INC | $99.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.88 | 2025 | Hyqvia |
| Electronic Waveform Lab, INC. | $17.18 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anza Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.